Free Trial

Denali Therapeutics Inc. (NASDAQ:DNLI) Stock Rated "Moderate Buy" by Wall Street Analysts

Denali Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts give Denali Therapeutics a “Moderate Buy” consensus: Of 17 analysts, 13 rate the stock a buy, one a strong buy, two a hold and one a sell. Their average one-year price target is $35.71.
  • Denali reported quarterly EPS of $0.37, beating the consensus estimate of a $0.27 loss, while revenue of $17.78 million exceeded the $12.67 million estimate.
  • Institutional investors own 92.92% of the stock. Insider Alexander O. Schuth sold 2,768 shares under a pre-arranged trading plan, reducing his holdings by 0.98%.
  • MarketBeat previews top five stocks to own in December.

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seventeen analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $35.71.

Several research analysts have recently commented on the stock. BTIG Research reaffirmed a "buy" rating and issued a $39.00 price target on shares of Denali Therapeutics in a report on Wednesday, November 4th. Robert W. Baird set a $34.00 price target on Denali Therapeutics in a report on Friday, August 7th. Wedbush boosted their price objective on Denali Therapeutics from $23.00 to $24.00 and gave the company an "outperform" rating in a research report on Wednesday, November 4th. UBS Group increased their target price on Denali Therapeutics from $25.00 to $34.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Finally, Wall Street Zen raised Denali Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, October 24th.

View Our Latest Stock Analysis on DNLI

Insider Buying and Selling at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,768 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $23.44, for a total value of $64,881.92. Following the transaction, the insider owned 278,995 shares of the company's stock, valued at $6,539,642.80. The trade was a 0.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.70% of the stock is currently owned by company insiders.

Institutional Trading of Denali Therapeutics

A number of hedge funds have recently made changes to their positions in DNLI. BlackRock Inc. bought a new stake in Denali Therapeutics in the 2nd quarter valued at $360,759,000. Dimensional Fund Advisors LP raised its stake in shares of Denali Therapeutics by 13.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,692,175 shares of the company's stock valued at $51,687,000 after buying an additional 317,872 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in shares of Denali Therapeutics by 1.9% during the 3rd quarter. Fisher Asset Management LLC now owns 2,460,545 shares of the company's stock worth $50,859,000 after acquiring an additional 46,383 shares during the period. ADAR1 Capital Management LLC lifted its holdings in shares of Denali Therapeutics by 3,490.9% during the 1st quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company's stock worth $35,932,000 after acquiring an additional 1,819,339 shares during the period. Finally, Aberdeen Group plc lifted its holdings in shares of Denali Therapeutics by 13.0% during the 3rd quarter. Aberdeen Group plc now owns 1,520,605 shares of the company's stock worth $31,431,000 after acquiring an additional 175,124 shares during the period. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Stock Performance

Shares of DNLI opened at $18.74 on Monday. The company has a market capitalization of $3.00 billion, a price-to-earnings ratio of -10.83 and a beta of 1.08. The company's 50 day simple moving average is $19.77 and its 200 day simple moving average is $21.25. Denali Therapeutics has a 1 year low of $15.34 and a 1 year high of $27.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.94 and a current ratio of 6.21.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported $0.37 EPS for the quarter, topping the consensus estimate of ($0.27) by $0.64. The firm had revenue of $17.78 million for the quarter, compared to analyst estimates of $12.67 million. During the same quarter in the prior year, the company earned ($0.74) earnings per share. On average, sell-side analysts predict that Denali Therapeutics will post -2.62 EPS for the current year.

Denali Therapeutics Company Profile

(Get Free Report)

Denali Therapeutics is a biotechnology company focused on developing medicines for neurodegenerative diseases and other disorders involving the nervous system. Founded in 2015, the company is headquartered in South San Francisco, California. Its research and development programs target conditions including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and lysosomal storage disorders. Denali's portfolio includes investigational drug candidates that aim to address underlying disease processes, as well as its TransportVehicle platform, designed to help therapeutic molecules cross the blood-brain barrier.

Recommended Stories

Analyst Recommendations for Denali Therapeutics (NASDAQ:DNLI)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Denali Therapeutics Right Now?

Before you consider Denali Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.

While Denali Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines